Synairgen plc Result of AGM (3874C)
18 Junio 2021 - 4:29AM
UK Regulatory
TIDMSNG
RNS Number : 3874C
Synairgen plc
18 June 2021
Press release
Synairgen plc
('Synairgen' or the 'Company')
Result of AGM
Southampton, UK - 18 June 2021: Synairgen plc (LSE: SNG), is
pleased to announce that all resolutions proposed at its Annual
General Meeting, held earlier today, were duly passed.
The full results of the proxy voting can be found on the
Company's website here .
A replay of the AGM webinar is now available here .
-Ends-
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and
development company founded by University of Southampton Professors
Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product
candidate, SNG001 (inhaled interferon beta) for the treatment of
COVID-19. SNG001 is potentially the first host-targeted
broad-spectrum antiviral treatment delivered directly into the
lungs. The Company is evaluating nebulised SNG001 in its Phase III
clinical programme, which has been deemed an Urgent Public Health
study by the UK's National Institute for Health Research (NIHR).
SNG001 has also been granted Fast Track status from the US Food and
Drug Administration (FDA). In a Phase II trial, COVID-19 patients
with marked/severe breathlessness demonstrated a threefold greater
chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGZZGMVLRNGMZG
(END) Dow Jones Newswires
June 18, 2021 05:29 ET (09:29 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024